Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
HDAC
Research
Could inhibiting both HDAC and PD-1 improve I-O treatments?
OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.
Arlene Weintraub
Jun 24, 2019 10:30am
Viracta's combo garners high response in EBV-linked lymphoma
Jun 3, 2019 11:39am
Xynomic preps broad push for HDAC cancer drug
Jun 1, 2018 10:26am
Syndax pals up with Nektar on entinostat combo trial
May 31, 2018 10:10am
Syndax touts possible biomarker data in HDAC/PD-1 combo in NSCLC
May 17, 2018 10:29am